Expand BFRIW Menu
BFRIW MENU

BFRIW Latest Press Releases

-- March 19, 2026 --

Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update Globe Newswire 9:25 AM

-- March 9, 2026 --

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 Globe Newswire 5:25 PM
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz Photodynamic Therapy for moderate to severe Acne Vulgaris Globe Newswire 9:15 AM

-- February 26, 2026 --

U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable Globe Newswire 9:15 AM

-- February 17, 2026 --

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz for Actinic Keratoses on Trunk and Extremities Globe Newswire 9:15 AM

-- February 11, 2026 --

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz PDT in Superficial Basal Cell Carcinoma Globe Newswire 9:15 AM

-- February 9, 2026 --

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint Globe Newswire 9:15 AM

-- January 13, 2026 --

Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth Globe Newswire 8:30 AM

-- January 8, 2026 --

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones Globe Newswire 8:45 AM

-- December 18, 2025 --

Biofrontera Inc. Completes Transfer of Ameluz and RhodoLED FDA approval and Associated Intellectual Property Portfolio Globe Newswire 8:45 AM

-- December 4, 2025 --

Last Patient Completes Biofrontera's Phase 1 Pharmacokinetics Study of Ameluz for Treatment of Actinic Keratoses on the Trunk and Extremities Globe Newswire 9:00 AM

-- December 2, 2025 --

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz-PDT Globe Newswire 8:45 AM
Market Data Delayed 15 Minutes